Healio Geographic Atrophy: Latest Treatments for Personalized Approaches
Geographic atrophy (GA) is a progressive, degenerative disease that leads to a gradual and irreversible decline of visual function. Utilization of multimodal imaging for the diagnosis and monitoring for progression of GA is critical in these patients, with optical coherence tomography currently being recommended for the detection of biomarkers associated with progression.
Experts in the field will present real-world cases highlighting assessment of GA associated risk factors, utilization of evidence-based imaging tools to accurately detect and monitor the progression of GA secondary to AMD, and evaluation of the latest clinical data to guide selection of therapies for individualized management.
Key Features
Geographic atrophy (GA) is a progressive, degenerative disease that leads to a gradual and irreversible decline of visual function. Utilization of multimodal imaging for the diagnosis and monitoring for progression of GA is critical in these patients, with optical coherence tomography currently being recommended for the detection of biomarkers associated with progression. Recently, the FDA approved 2 novel therapies that target components of the complement system for the management of GA secondary to age-related macular degeneration (AMD) transforming the management paradigm for patients with this condition. In this CE activity, experts in the field will present real-world cases highlighting assessment of GA associated risk factors, utilization of evidence-based imaging tools to accurately detect and monitor the progression of GA secondary to AMD, and evaluation of the latest clinical data to guide selection of therapies for individualized management.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize the underlying mechanisms and risk factors for GA secondary to AMD.
- Employ evidence-based imaging tools to accurately detect GA and monitor the progression of disease.
- Select novel treatments to manage patients with GA based on their latest clinical evidence.
Target Audience
The intended audience for this activity includes retina specialists and ophthalmologists involved in the management of patients with, or at risk for, geographic atrophy secondary to AMD.
Additional credit info
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.